European journal of endocrinology · 2019
Cabergoline in severe ectopic or occult Cushing's syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ilie Mirela Diana, Raverot Véronique, Tronc François, Vasiljevic Alexandre, Borson-Chazot Françoise, Raverot Gérald
Аннотация
CONTEXT: Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated.
CASE SERIES: In this case series, cabergoline was used in combination with steroidogenesis inhibitors in nine patients with severe Cushing's syndrome of ectopic or occult origin. Cabergoline's effectiveness enabled rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism in three of the cases.
REVIEW OF THE LITERATURE: In the literature, we found only 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, alone or in combination. Yet of these 11 cases, 10 responded.
CONCLUSIONS: Although limited, the existing experience highlights the potential value of cabergoline in the treatment of ectopic or occult Cushing's syndrome.
CASE SERIES: In this case series, cabergoline was used in combination with steroidogenesis inhibitors in nine patients with severe Cushing's syndrome of ectopic or occult origin. Cabergoline's effectiveness enabled rapid withdrawal of the steroidogenesis inhibitors and long-term control of the hypercortisolism in three of the cases.
REVIEW OF THE LITERATURE: In the literature, we found only 11 cases of ectopic or occult Cushing's syndrome treated with dopamine receptor agonists, alone or in combination. Yet of these 11 cases, 10 responded.
CONCLUSIONS: Although limited, the existing experience highlights the potential value of cabergoline in the treatment of ectopic or occult Cushing's syndrome.
Предметные рубрики MeSH
ACTH Syndrome, EctopicAdultAgedCabergolineCarcinoid TumorCushing SyndromeDopamine AgonistsFemaleHumansHydrocortisoneKetoconazoleLiver NeoplasmsLung NeoplasmsMaleMiddle AgedNeuroendocrine TumorsPancreatic Intraductal NeoplasmsRectal NeoplasmsSteroid Synthesis InhibitorsThymus NeoplasmsTreatment Outcome